Cymerais fy mhenderfyniad yn 2017 oherwydd cyngor oddi wrth Grŵp Strategaeth Feddyginiaethau Cymru (AWMSG).  Ar y pryd, cyngor AWMSG oedd na ellid cymeradwyo defnyddio PrEP fel rheol oherwydd ansicrwydd am lefelau’r cost-effeithiolrwydd yn eu gwerthusiad o’r unig feddyginiaeth drwyddedig ar gael i PrEP yr adeg honno, y cynnyrch perchnogol Truvada®.
My decision in 2017 was taken in light of advice from the All-Wales Medicines Strategy Group (AWMSG). At that time, AWMSG’s advice was the use of PrEP could not be recommended for routine use given uncertainties around the levels of cost-effectiveness in their appraisal of the only licensed medicine available for PrEP at the time, the proprietary product Truvada®.